ADARx Pharmaceuticals Inc. – Material Contracts Watch

from S-1/A 15 pages ADARx Pharmaceuticals, Inc. Severance Plan and Summary Plan Description Approved by the Board of Directors: September 2, 2026

from S-1/A 3 pages September 9, 2026 Rob Ackles [***] Re: Confirmatory Offer Letter Dear Rob, You Are Currently Employed by ADARx Pharmaceuticals, Inc. (The “Company”) as Chief People Officer. This Letter Confirms the Terms and Conditions of Your Employment in That Role

from S-1/A 3 pages September 9, 2026 Dr. Rui Zhu [***] Re: Confirmatory Offer Letter Dear Rui, You Are Currently Employed by ADARx Pharmaceuticals, Inc. (The “Company”) as Chief Technology Officer. This Letter Confirms the Terms and Conditions of Your Employment in That Role

from S-1/A 3 pages September 11, 2026 Ryan Fisk [***] Re: Confirmatory Offer Letter Dear Ryan, You Are Currently Employed by ADARx Pharmaceuticals, Inc. (The “Company”) as Chief Financial Officer and Chief Business Officer. This Letter Confirms the Terms and Conditions of Your Employment in That Role

from S-1/A 3 pages September 9, 2026 Dr. Robert Macleod [***] Re: Confirmatory Offer Letter Dear Robert, You Are Currently Employed by ADARx Pharmaceuticals, Inc. (The “Company”) as Chief Scientific Officer. This Letter Confirms the Terms and Conditions of Your Employment in That Role

from S-1/A 3 pages September 10, 2026 Dr. Zhen LI [***] Re: Confirmatory Offer Letter Dear Zhen, You Are Currently Employed by ADARx Pharmaceuticals, Inc. (The “Company”) as Chief Executive Officer. This Letter Confirms the Terms and Conditions of Your Employment in That Role

from S-1/A 3 pages ADARx Pharmaceuticals, Inc. Non-Employee Director Compensation Policy

from S-1/A 16 pages ADARx Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan Adopted by the Board of Directors: September 13, 2026 Approved by the Stockholders: September 16, 2026

from S-1/A 12 pages ADARx Pharmaceuticals, Inc. Stock Option Grant Notice

from S-1/A 30 pages ADARx Pharmaceuticals, Inc. 2026 Equity Incentive Plan Adopted by the Board of Directors: September 13, 2026 Approved by the Stockholders: September 16, 2026

from S-1/A 15 pages Common Stock Purchase Agreement

from S-1 3 pages Ying Huang, PH.D. [***] Dr. Huang: We Are Delighted That You Have Agreed to Join the Board of Directors (The “Board”) of ADARx Pharmaceuticals, Inc. (The “Company”). This Letter Sets Forth the Agreement Between You and the Company Regarding Your Board Membership (The “Agreement”)

from S-1 133 pages Collaboration and License Option Agreement Between ADARx Pharmaceuticals, Inc. and the Puerto Rico Branch of Abbvie Biotechnology Ltd Dated as of May 9, 2025

from S-1 61 pages Lease Agreement

from S-1 3 pages Mary Tagliaferri, M.D. [***] Dr. Tagliaferri: We Are Delighted That You Have Agreed to Join the Board of Directors (The “Board”) of ADARx Pharmaceuticals, Inc. (The “Company”). This Letter Sets Forth the Agreement Between You and the Company Regarding Your Board Membership (The “Agreement’)

from S-1 9 pages Separation Agreement and Release

from S-1 13 pages 3. Bonuses. You Will Be Eligible for an Annual Discretionary Bonus of Up to 35% of Your Base Salary (The “Annual Bonus”), Which Shall Be Prorated Based on the Number of Days You Are Actually Employed During the Calendar Year. Whether You Receive an Annual Bonus for Any Given Year, and the Amount of Any Such Annual Bonus, Will Be Determined by the Company’s Board in Its Sole Discretion, Based Upon a Combination of Company Results and Individual Performance Against the Applicable Performance Goals Established by the Company’s Board. You Must Remain an Active Employee Continuously Through the End of Any Given Calendar Year in Order to Earn an Annual Bonus for That Year, and Any Such Bonus Will Be Paid Prior to March 15 of the Following Year. You Will Not Be Eligible For, and Will Not Earn, Any Annual Bonus (Including a Prorated Bonus) for a Given Calendar Year if Your Employment Terminates for Any Reason Before the End of Such Calendar Year

from S-1 13 pages ADARx Pharmaceuticals, Inc. Stock Option Grant Notice

from S-1 21 pages ADARx Pharmaceuticals, Inc. Amended and Restated 2020 Equity Incentive Plan Adopted by the Board of Directors: July 24, 2020 Approved by the Stockholders: July 24, 2020 Amended by the Board of Directors: November 4, 2020 Amended by the Stockholders: November 4, 2020 Amended by the Board of Directors: May 14, 2021 Amended by the Stockholders: May 14, 2021 Amended by the Board of Directors: July 30, 2021 Amended by the Stockholders: July 30, 2021 Amended by the Board of Directors: August 2, 2023 Amended by the Stockholders: August 2, 2023 Termination Date: July 23, 2030

from S-1 8 pages Indemnification Agreement